Protalix BioTherapeutics, Inc. (PLX) Cash and securities
- Total cash · latest quarter (USD): Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities. Period ending 2026-06-30..
- Cash per share · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities / reported quarter-end common shares. Period ending 2026-06-30..
Cash and securities
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total cash · latest quarter (USD) | (m) | Cash and cash equivalents plus current marketable securities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Cash per share · latest quarter | (m) | Cash and cash equivalents plus current marketable securities / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash and equivalents | 27.42M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Cash and current securities | (m) | Cash and Cash Equivalents, at Carrying Value |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total cash | Cash per share | Cash and equivalents (USD) | Short-term securities (USD) | Quarter-end shares (shares) |
|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $27.42M | (m) | (m) |
| 2026-03-31 | (m) | (m) | $41.00M | (m) | (m) |
| 2025-12-31 | (m) | (m) | $14.68M | (m) | (m) |
| 2025-09-30 | (m) | (m) | $13.65M | (m) | (m) |
| 2025-06-30 | (m) | (m) | $17.89M | (m) | (m) |
| 2025-03-31 | (m) | (m) | $19.46M | (m) | (m) |
| 2024-12-31 | (m) | (m) | $19.76M | (m) | (m) |
| 2024-09-30 | (m) | (m) | $27.41M | (m) | (m) |
| 2024-06-30 | (m) | (m) | $23.40M | (m) | (m) |
| 2024-03-31 | (m) | (m) | $27.21M | (m) | (m) |
| 2023-12-31 | (m) | (m) | $23.63M | (m) | (m) |
| 2023-09-30 | (m) | (m) | $20.41M | (m) | (m) |
| 2023-06-30 | (m) | (m) | $48.18M | (m) | (m) |
| 2023-03-31 | (m) | (m) | $33.04M | (m) | (m) |
| 2022-12-31 | (m) | (m) | $17.11M | (m) | (m) |
| 2022-09-30 | (m) | (m) | $10.72M | (m) | (m) |
| 2022-06-30 | (m) | (m) | $12.49M | (m) | (m) |
| 2022-03-31 | (m) | (m) | $16.89M | (m) | (m) |
| 2021-12-31 | (m) | (m) | $38.98M | (m) | (m) |
| 2021-09-30 | (m) | (m) | $10.64M | (m) | (m) |
| 2021-06-30 | (m) | (m) | $33.88M | (m) | (m) |
| 2021-03-31 | (m) | (m) | $19.83M | (m) | (m) |
| 2020-12-31 | (m) | (m) | $18.27M | (m) | (m) |
| 2020-09-30 | (m) | (m) | $13.53M | (m) | (m) |
| 2020-06-30 | (m) | (m) | $4.84M | (m) | (m) |
| 2020-03-31 | (m) | (m) | $14.17M | (m) | (m) |
| 2019-12-31 | (m) | (m) | $17.79M | (m) | (m) |
| 2019-09-30 | (m) | (m) | $21.44M | (m) | (m) |
| 2019-06-30 | (m) | (m) | $25.10M | (m) | (m) |
| 2019-03-31 | (m) | (m) | $30.36M | (m) | (m) |
| 2018-12-31 | (m) | (m) | $37.81M | (m) | (m) |
| 2018-09-30 | (m) | (m) | $41.87M | (m) | (m) |
| 2018-06-30 | (m) | (m) | $28.33M | (m) | (m) |
| 2018-03-31 | (m) | (m) | $41.32M | (m) | (m) |
| 2017-12-31 | (m) | (m) | $51.16M | (m) | (m) |
| 2017-09-30 | (m) | (m) | $33.48M | (m) | (m) |
| 2017-06-30 | (m) | (m) | $34.53M | (m) | (m) |
| 2017-03-31 | (m) | (m) | $48.02M | (m) | (m) |
| 2016-12-31 | (m) | (m) | $63.28M | (m) | (m) |
| 2016-09-30 | (m) | (m) | $51.32M | (m) | (m) |
| 2016-06-30 | (m) | (m) | $54.63M | (m) | (m) |
| 2016-03-31 | (m) | (m) | $66.67M | (m) | (m) |
| 2015-12-31 | (m) | (m) | $76.37M | (m) | (m) |
| 2015-09-30 | (m) | (m) | $34.25M | (m) | (m) |
| 2015-06-30 | (m) | (m) | $43.24M | (m) | (m) |
| 2015-03-31 | (m) | (m) | $47.96M | (m) | (m) |
| 2014-12-31 | (m) | (m) | $54.77M | (m) | (m) |
| 2014-09-30 | (m) | (m) | $60.32M | (m) | (m) |
| 2014-06-30 | (m) | (m) | $71.14M | (m) | (m) |
| 2014-03-31 | (m) | (m) | $77.69M | (m) | (m) |
| 2013-12-31 | (m) | (m) | $86.40M | (m) | (m) |
| 2013-09-30 | (m) | (m) | $91.40M | (m) | (m) |
| 2013-06-30 | (m) | (m) | $33.13M | (m) | (m) |
| 2013-03-31 | (m) | (m) | $41.87M | (m) | (m) |
| 2012-12-31 | (m) | (m) | $52.03M | (m) | (m) |
| 2012-09-30 | (m) | (m) | $50.22M | (m) | (m) |
| 2012-06-30 | (m) | (m) | $59.28M | (m) | (m) |
| 2012-03-31 | (m) | (m) | $45.60M | (m) | (m) |
| 2011-12-31 | (m) | (m) | $27.00M | (m) | (m) |
| 2011-09-30 | (m) | (m) | $34.56M | (m) | (m) |
| 2011-06-30 | (m) | (m) | $44.05M | (m) | (m) |
| 2011-03-31 | (m) | (m) | $50.23M | (m) | (m) |
| 2010-12-31 | (m) | (m) | $35.90M | (m) | (m) |
| 2010-09-30 | (m) | (m) | $44.40M | (m) | (m) |
| 2010-06-30 | (m) | (m) | $54.96M | (m) | (m) |
| 2009-12-31 | (m) | (m) | $81.27M | (m) | (m) |
| 2008-12-31 | (m) | (m) | $42.60M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |